Background

The pharmacokinetics and bioavailability of N-acetylcysteine (NAC) have been determined after its intravenous and oral administration to 6 healthy volunteers. According to a randomized cross-over design each subject received NAC 200 mg i.v. and 400 mg p.o., and blood samples were collected for 30 h. Reduced NAC had a volume of distribution (VSS) of 0.59 l.kg-1 and a plasma clearance of 0.84 l.h-1.kg-1. The terminal half-life after intravenous administration was 1.95 h. The oral bioavailability was 4.0%. Based on total NAC concentration, its volume of distribution (VSS) was 0.47 l.kg-1 and its plasma clearance was 0.11 l.h-1.kg-1. The terminal half-life was 5.58 h after intravenous administration and 6.25 h after oral administration. Oral bioavailability of total NAC was 9.1%.

No abstract

I n this article the aim is to report from two empirical studies of annual reporting of intellectual capital (1C), with particular emphasis on human resources (HR) in Swedish companies. The studies were made on the largest Swedish companies on the stock market's A-list, during the years 1990, 1994 and 1998. The material used was the external annual reports. In the studies we wanted to assess the extent to which large companies are publicly reporting their IC. The research aimed to investigate the reporting practices in Swedish companies. The research question was to determine if company representatives' desire to make HR more transparent is merely an expression that is not supported by real conviction. The studies showed that there is a very low share of information disclosed about human resources in the corporate annual reports. A tendency to increase was evident, but it is, on average, below 4%. None of the 18 largest companies were above 7%, which reveals that there is a lack of good examples to be found in this group of companies and very little changes had taken place during the past 10 years. It must be concluded that a great deal is often said about the importance of having a more transparent HR or human capital in companies, but the evidence suggests that in the real world this is still not the case.

The new once daily ER formulation of tolterodine 4mg shows pharmacokinetic equivalence (AUC24) to the existing IR tablet given at a dose of 2mg twice daily. Findings of lower Cmax for tolterodine ER may explain the significantly lower rate of dry mouth subsequently observed in patients with overactive bladder.